@entity4206 in Conjunction With @entity2225 and XXXX Distinguishes Primary @entity5 of the Skin.

@entity5 @entity1489 @entity4206 @entity2225 @entity5962 @entity17142 @entity3546 @entity272 @entity1491
UNASSIGNED: Although @entity1491 ( @entity1491 ) show typical histomorphologic features, they sometimes remain difficult in distinction from benign adnexal @entity1489 of follicular origin like @entity17142 ( @entity17142 ) or trichoblastoma (TB). Consequently, an immunohistochemical marker panel separating described entities would be helpful in clinical routine. Thus, we stained 22 @entity272 ( @entity1491 , @entity17142 , and TB) against @entity3546 , @entity2225 , @entity5962 , @entity4206 , and @entity4206 . The staining pattern was described and quantified using an immunohistochemical score. Although @entity4206 and @entity4206 revealed a strong staining intensity of all @entity272 without distinction between @entity1491 and benign lesions (P=1.000), established Merkel cell marker @entity2225 illustrated a loss of staining in @entity1491 compared with @entity17142 and TB (P=0.007). In contrast, @entity1491 exhibited an increased expression of @entity5962 in relation to @entity17142 and TB (P=0.009). Single application of @entity2225 or @entity5962 could predict diagnosis of @entity1491 in 81.8% or 72.7%, respectively. Combining consecutive staining of @entity5962 and @entity2225 could even enhance specificity toward diagnosis of @entity17142 or TB. Hence, findings of our study imply that sequential staining of @entity2225 and @entity5962 prevents false-positive classification of @entity1491 . Furthermore, our study demonstrated that @entity4206 exhibits the same staining pattern in @entity1491 , @entity17142 , and TB. Therefore, @entity4206 might replace @entity4206 equivalently establishing diagnosis of primary @entity5 of the skin in the form of @entity1491 as well as benign @entity5 . As a result, the depicted immunohistochemical marker panel may be applied for @entity1489 as a diagnostic adjunct especially in surgically challenging body regions.
